Prime Medicine (NASDAQ:PRME) Shares Up 8.4% - Should You Buy?

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price traded up 8.4% during mid-day trading on Wednesday . The stock traded as high as $4.52 and last traded at $4.51. 1,555,082 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 3,151,651 shares. The stock had previously closed at $4.16.Get Prime Medicine alerts:Analysts Set New Price TargetsA number of equities analysts have recently commented on the stock. Lifesci Capital raised shares of Prime Medicine to a "strong-buy" rating in a research report on Tuesday, December 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prime Medicine in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Prime Medicine from a "hold" rating to a "sell" rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prime Medicine presently has a consensus rating of "Moderate Buy".View Our Latest Stock Report on PRMEPrime Medicine Stock Up 5.5%The firm's 50-day moving average price is $3.76. The firm has a market cap of $792.44 million, a PE ratio of -3.05 and a beta of 2.71. Prime Medicine (NASDAQ:PRME - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.04). The firm had revenue of $1.23 million during the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%. About Prime Medicine (Get Free Report)We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.Featured StoriesFive stocks we like better than Prime MedicineThis $15 Stock Could Go Down as the #1 Stock of 2026If You Keep Cash In A U.S. Bank Account… Read This NOWPunch these codes into your ordinary brokerage accountThis AI Opportunity Was Built to Evolve With DemandNEW LAW: Congress Approves Setup For Digital Dollar?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Prime Medicine Right Now?Before you consider Prime Medicine, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here